Archive for category: Contract Awards

Ampersand Biosciences awarded Development of Monoclonal Antibodies to Chemokines in the Ferret Model of Respiratory Disease

/in

The two-year project, titled Development of monoclonal antibodies to chemokines in the ferret model of respiratory disease, is funded for $600,000. While the work uses a specialized small animal model, its impact is broad. According to Tori Race, PhD., the contract will expand the portfolio of research tools to further support infectious disease research. It also complements Ampersand’s existing product line, which is already in use by scientists worldwide. Contract # 75N93025C00018.

NAICS: 541714 – Research and Development in Biotechnology (except Nanobiotechnology)
PSC: AN11 – Health R&D Services; Health Care Services; Basic Research

Ampersand Biosciences awarded SBIR Grant for Immunologic Analysis of Non-Mammalian and Underrpresented Mammalian Models

/in

Ampersand Biosciences was awarded a contract by the National Institute of Allergy and Infectious Diseases (NIAID) on September 20, 2022 until Dece,ber 15, 2024 for immunologic analysis of non-mammalian and underrepresented mammalian models.

NAICS: 541714 – Research and Development in Biotechnology (except Nanobiotechnology)
PSC: AN12 – Health R&D Services; Health Care Services; Applied Research

Ampersand Biosciences awarded contract by NIAID for further characterization and validation of monoclonal antibodies to study respiratory

/in

Ampersand Biosciences was awarded a contract by the National Institute of Allergy and Infectious Diseases (NIAID) on September 30, 2024 until September 29, 2026 to further characterize and validate monoclonal antibodies to study respiratory.

NAICS: 541714 – Research and Development in Biotechnology (except Nanobiotechnology)
PSC: AN12 – Health R&D Services; Health Care Services; Applied Research

Ampersand Biosciences awarded a contract by the NIAID for the development of Ferret Reagents for us in the characterization of immune responses to respiratory infections in the ferret model

/in

Ampersand Biosciences was awarded a contract by the National Institute of Allergy and Infectious Diseases (NIAID) on July 1, 2020 until August 31, 2022 to address an urgent need to develop reagents to better understand and describe the immunologic analyses of respiratory infections in the ferret. Phase 1 will produce commercially available ferret-specific immunoreagents. Phase 2 will develop Luminex kits for quantitative multiplex analyses of innate immune mediators.

NAICS: 541714 – Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC: AN12 – Health R&D Services; Health Care Services; Applied Research

Ampersand Biosciences awarded contract for Map Analysis by the CDC

/in

Ampersand Biosciences was awarded a contract by the CDC Office of Acquisition Services (OAS) [HHS – CDC] on May 30, 2018 until November 30, 2018 for map analysis.

NAICS: 541714 – Research and Development in Biotechnology (except Nanobiotechnology)
PSC: B504 – Special Studies/Analysis – Chemical/Biological

Ampersand Biosciences awarded contract for Analyte Identification Services by ACC

/in

Ampersand Biosciences was awarded a contract by the ACC Aberdeen Proving Ground (APG) [DoD – USA – AMC – ACC] on July 20, 2017 until July 31, 2019 for analyte identification services.

NAICS: 541711 – Research And Development In Biotechnology
PSC: AN42 – Health R&D Services; Health Care – Other; Applied Research

Want to stay up to date? Subscribe to our newsletter!

important links

ampersand biosciences